Skip to content

Cladribine

Leustatin, Mavenclad, Litak (cladribine) is a small molecule pharmaceutical. Cladribine was first approved as Leustatin on 1993-02-26. It is used to treat b-cell chronic lymphocytic leukemia, hairy cell leukemia, multiple sclerosis, and non-hodgkin lymphoma in the USA. It has been approved in Europe to treat hairy cell leukemia and multiple sclerosis. Cladribine's patents are valid until 2026-10-16 (FDA).
Trade Name Litak, Mavenclad
Common Name Cladribine
Indication b-cell chronic lymphocytic leukemia, hairy cell leukemia, multiple sclerosis, non-hodgkin lymphoma
Drug Class Ribofuranil derivatives (pyrazofurin type)
Cladribine
Get full access now